NVCT - Nuvectis Pharma Inc

9.65
0.570   5.907%

Share volume: 94,855
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$9.08
0.57
0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 26%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.70%
1 Month
9.91%
3 Months
27.31%
6 Months
48.23%
1 Year
31.65%
2 Year
-4.93%
Key data
Stock price
$9.65
P/E Ratio 
0.00
DAY RANGE
$9.07 - $9.88
EPS 
-$1.38
52 WEEK RANGE
$5.55 - $11.52
52 WEEK CHANGE
$24.68
MARKET CAP 
193.392 M
YIELD 
N/A
SHARES OUTSTANDING 
26.492 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
3.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$61,663
AVERAGE 30 VOLUME 
$56,567
Company detail
CEO: Ronald E. Bentsur
Region: US
Website: nuvectis.com
Employees: 8
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nuvectis Pharma focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Recent news